

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on Apr 17, 2025

Jurkat

RRID:CVCL_0065

Type: Cell Line

Proper Citation

(RRID:CVCL_0065)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0065

Proper Citation: (RRID:CVCL_0065)

Sex: Male

Defining Citation: [PMID:68013](#), [PMID:204546](#), [PMID:1086134](#), [PMID:1103999](#), [PMID:1915666](#), [PMID:2144611](#), [PMID:2985879](#), [PMID:3159941](#), [PMID:3165345](#), [PMID:3874327](#), [PMID:8127147](#), [PMID:8547074](#), [PMID:8558913](#), [PMID:8641406](#), [PMID:8957066](#), [PMID:9510473](#), [PMID:9583678](#), [PMID:9685479](#), [PMID:9738977](#), [PMID:9787181](#), [PMID:9933131](#), [PMID:10071127](#), [PMID:10739008](#), [PMID:11021758](#), [PMID:11226526](#), [PMID:15028022](#), [PMID:15472075](#), [PMID:16408098](#), [PMID:17117183](#), [PMID:17170727](#), [PMID:19220422](#), [PMID:19473701](#), [PMID:19608861](#), [PMID:22278370](#), [PMID:22460905](#), [PMID:22675565](#), [PMID:22944676](#), [PMID:23325432](#), [PMID:24618588](#), [PMID:26074081](#), [PMID:27397505](#), [PMID:28357668](#), [PMID:29967540](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30844424](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:31978347](#), [PMID:35354797](#), [PMID:35839778](#)

Comments: Anecdotal: Have been flown in space on Cosmos-2044 to study the inhibition of phorbol ester-induced cell activation in microgravity (PubMed=1915666)., Omics: Virome analysis using proteomics., Omics: Ubiquitination analysis by proteomics., Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: N-glycan profiling., Omics: HLA class I peptidome analysis by proteomics., Omics: Deep quantitative proteome analysis., Omics: Deep proteome analysis., Omics: Deep phosphoproteome analysis., Omics: DNA methylation analysis., Omics: Deep exome analysis., Omics: Acetylation analysis by proteomics., Population: Caucasian., Part of: LL-100 blood cancer cell line panel., Part of: International Histocompatibility Workshop cell lines., Part of: ENCODE project common cell types; tier 3., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line

Encyclopedia - CCLE), Group: Space-flown cell line (cellonaut).

Category: Cancer cell line

Name: Jurkat

Synonyms: JURKAT, JM, JM-Jurkat, Jurkat-FHCRC, Jurkat FHCRC, FHCRC-11, FHCRC subclone 11, FCCH1024

Cross References: BTO:BTO_0000661, CLO:CLO_0007029, CLO:CLO_0007043, CLO:CLO_0050978, CLO:CLO_0050993, CLO:CLO_0051001, EFO:EFO_0002796, MCCL:MCC:0000503, CLDB:cl2950, CLDB:cl2959, CLDB:cl2960, CLDB:cl2961, CLDB:cl5212, Abcam:ab271143, Abcam:ab275468, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BEI_Resources:ARP-4668, BioGRID_ORCS_Cell_line:1255, BioSample:SAMN03472181, BioSample:SAMN03472286, BioSample:SAMN03473341, BioSample:SAMN10988565, cancercellines:CVCL_0065, CCRID:1101HUM-PUMC000347, Cell_Model_Passport:SIDM01016, ChEMBL-Cells:ChEMBL3307526, ChEMBL-Targets:ChEMBL397, CLS:302147, CLS:305018, Cosmic:683539, Cosmic:721707, Cosmic:755289, Cosmic:801727, Cosmic:850196, Cosmic:913426, Cosmic:919152, Cosmic:922675, Cosmic:933540, Cosmic:991544, Cosmic:998737, Cosmic:999757, Cosmic:1012072, Cosmic:1037693, Cosmic:1115592, Cosmic:1118463, Cosmic:1118464, Cosmic:1127262, Cosmic:1130236, Cosmic:1132774, Cosmic:1175129, Cosmic:1191689, Cosmic:1224368, Cosmic:1226860, Cosmic:1330489, Cosmic:1375588, Cosmic:1483364, Cosmic:1524798, Cosmic:1639637, Cosmic:1641380, Cosmic:1664522, Cosmic:1760524, Cosmic:1811157, Cosmic:2039520, Cosmic:2165713, Cosmic:2301569, Cosmic:2361366, Cosmic:2602916, Cosmic:2750872, Cosmic-CLP:998184, DepMap:ACH-000995, DSMZ:ACC-282, DSMZCellDive:ACC-282, ECACC:86010201, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:998184, GEO:GSM1991, GEO:GSM236783, GEO:GSM236819, GEO:GSM482494, GEO:GSM749672, GEO:GSM887188, GEO:GSM888261, GEO:GSM1040307, GEO:GSM1040377, GEO:GSM1374580, GEO:GSM1669965, GEO:GSM5137718, GEO:GSM5534218, GEO:GSM5534219, GEO:GSM5534220, GEO:GSM5534221, GEO:GSM5534222, GEO:GSM5534223, IARC_TP53:186, IBRC:C10155, ICLC:HTL01002, IHW:IHW00002, IZSLER:BS CL 131, KCB:KCB 94018YJ, LiGeA:CCLE_029, LINCS_LDP:LCL-2107, Lonza:142, MeSH:D019169, NCBI_Iran:C120, PharmacDB:JURKAT_712_2019, PRIDE:PRD000008, PRIDE:PRD000013, PRIDE:PXD000443, PRIDE:PRD000787, PRIDE:PXD000426, PRIDE:PXD001428, PRIDE:PXD001872, PRIDE:PXD002091, PRIDE:PXD002395, PRIDE:PXD006201, PRIDE:PXD023662, PRIDE:PXD030304, Progenetix:CVCL_0065, PubChem_Cell_line:CVCL_0065, RCB:RCB0537, RCB:RCB0806, RCB:RCB3052, TKG:TKG 0209, TOKU-E:3710, Wikidata:Q1632589

ID: CVCL_0065

Record Creation Time: 20250131T201111+0000

Record Last Update: 20250131T202613+0000

Ratings and Alerts

No rating or validation information has been found for Jurkat.

Warning: Discontinued: ICLC; HTL01002

Anecdotal: Have been flown in space on Cosmos-2044 to study the inhibition of phorbol ester-induced cell activation in microgravity (PubMed=1915666)., Omics: Virome analysis using proteomics., Omics: Ubiquitination analysis by proteomics., Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: N-glycan profiling., Omics: HLA class I peptidome analysis by proteomics., Omics: Deep quantitative proteome analysis., Omics: Deep proteome analysis., Omics: Deep phosphoproteome analysis., Omics: DNA methylation analysis., Omics: Deep exome analysis., Omics: Acetylation analysis by proteomics., Population: Caucasian., Part of: LL-100 blood cancer cell line panel., Part of: International Histocompatibility Workshop cell lines., Part of: ENCODE project common cell types; tier 3., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Space-flown cell line (cellonaut).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 7986 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Reinhold A, et al. (2025) Ionizing radiation and photodynamic therapy lead to multimodal tumor cell death, synergistic cytotoxicity and immune cell invasion in human bladder cancer organoids. Photodiagnosis and photodynamic therapy, 51, 104459.

Xu J, et al. (2024) Preclinical testing of CT1113, a novel USP28 inhibitor, for the treatment of T-cell acute lymphoblastic leukaemia. British journal of haematology, 204(6), 2301.

Kouro T, et al. (2024) Novel chimeric antigen receptor-expressing T cells targeting the malignant mesothelioma-specific antigen sialylated HEG1. International journal of cancer, 154(10), 1828.

Calbert ML, et al. (2024) 4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress. Molecular cancer therapeutics, 23(5), 683.

Chen Z, et al. (2024) SIGLEC15, negatively correlated with PD-L1 in HCC, could induce CD8+ T cell apoptosis to promote immune evasion. Oncoimmunology, 13(1), 2376264.

Hofman DA, et al. (2024) Translation of non-canonical open reading frames as a cancer cell

survival mechanism in childhood medulloblastoma. *Molecular cell*, 84(2), 261.

Lin MC, et al. (2024) Targeting tumor O-glycosylation modulates cancer-immune-cell crosstalk and enhances anti-PD-1 immunotherapy in head and neck cancer. *Molecular oncology*, 18(2), 350.

Tsao HW, et al. (2024) Targeting the aminopeptidase ERAP enhances antitumor immunity by disrupting the NKG2A-HLA-E inhibitory checkpoint. *Immunity*, 57(12), 2863.

Lee S, et al. (2024) B7H6 is the predominant activating ligand driving natural killer cell-mediated killing in patients with liquid tumours: evidence from clinical, in silico, in vitro, and in vivo studies. *EBioMedicine*, 110, 105459.

Archer S, et al. (2024) CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(8), 1595.

de Kivit S, et al. (2024) Immune suppression by human thymus-derived effector Tregs relies on glucose/lactate-fueled fatty acid synthesis. *Cell reports*, 43(9), 114681.

Köppke J, et al. (2024) Direct translation of incoming retroviral genomes. *Nature communications*, 15(1), 299.

Houbaert D, et al. (2024) An autophagy program that promotes T cell egress from the lymph node controls responses to immune checkpoint blockade. *Cell reports*, 43(4), 114020.

Takami M, et al. (2024) Anti-V α 24J β 18 TCR Antibody Tunes iNKT Cell Responses to Target and Kill CD1d-negative Tumors in an Fc γ RII (CD32)-dependent Manner. *Cancer research communications*, 4(2), 446.

Dötsch L, et al. (2024) Discovery of the sEH Inhibitor Epoxykynin as a Potent Kynurenine Pathway Modulator. *Journal of medicinal chemistry*, 67(6), 4691.

Hlozkova K, et al. (2024) Rewired glutamate metabolism diminishes cytostatic action of L-asparaginase. *Cancer letters*, 605, 217242.

Shahzad U, et al. (2024) CASCADES, a novel SOX2 super-enhancer-associated long noncoding RNA, regulates cancer stem cell specification and differentiation in glioblastoma. *Molecular oncology*.

Shin SW, et al. (2024) FIND-seq: high-throughput nucleic acid cytometry for rare single-cell transcriptomics. *Nature protocols*, 19(11), 3191.

Rodríguez-Blázquez A, et al. (2023) Crk proteins activate the Rap1 guanine nucleotide exchange factor C3G by segregated adaptor-dependent and -independent mechanisms. *Cell communication and signaling : CCS*, 21(1), 30.

Bhattacharya P, et al. (2023) Efferocytes release extracellular vesicles to resolve inflammation and tissue injury via prosaposin-GPR37 signaling. *Cell reports*, 42(7), 112808.